Nanosphere, Inc.  

(Public, NASDAQ:NSPH)   Watch this stock  
Find more results for NSPH
3.69
-0.13 (-3.40%)
Real-time:   3:12PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.63 - 3.90
52 week 3.50 - 35.60
Open 3.90
Vol / Avg. 176,688.00/148,666.00
Mkt cap 22.40M
P/E     -
Div/yield     -
EPS -8.24
Shares 5.86M
Beta 3.48
Inst. own 15%
Aug 4, 2015
Q2 2015 Nanosphere Inc Earnings Release (Estimated) Add to calendar
May 12, 2015
Q1 2015 Nanosphere Inc Earnings Call - Webcast
May 11, 2015
Q1 2015 Nanosphere Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -163.12% -273.41%
Operating margin -156.93% -263.75%
EBITD margin - -250.68%
Return on average assets -77.27% -76.76%
Return on average equity -130.71% -111.93%
Employees 169 -
CDP Score - -

Address

4088 Commercial Avenue
NORTHBROOK, IL 60062
United States - Map
+1-847-4009000 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Nanosphere, Inc. is engaged in providing targeted molecular diagnostic tests that can lead to earlier disease detection, optimal patient treatment and improved healthcare economics. It also conducts tests for the development of medicines. The Company’s platform, the Verigene System, enables clinicians to rapidly identify and treat the bacteria and viruses responsible for some of the most complex, costly and deadly infectious diseases. The Verigene System includes a bench-top molecular diagnostics workstation that is an advanced platform for genomic and protein testing. The Verigene System comprises a microfluidics processor, a touchscreen reader and disposable test cartridges. The Company is focused on the infectious disease diagnostics market.

Officers and directors

Michael K. McGarrity President, Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Ann Wallin Interim Chief Financial Officer, Chief Accounting Officer
Age: 41
Bio & Compensation  - Reuters
Kenneth Bahk Ph.D. Chief Strategy Officer
Age: 41
Bio & Compensation  - Reuters
Kristopher A. Wood Director
Age: 43
Bio & Compensation  - Reuters
Gene S. Cartwright Ph.D. Independent Director
Age: 61
Bio & Compensation  - Reuters
Andre de Bruin Independent Director
Age: 68
Bio & Compensation  - Reuters
Erik Holmlin Ph.D. Independent Director
Age: 47
Bio & Compensation  - Reuters
Lorin Jeffry Randall Independent Director
Age: 71
Bio & Compensation  - Reuters